Full-Time

Manager – Distribution Order Management

Posted on 7/5/2026

EVERSANA

EVERSANA

1,001-5,000 employees

Commercial services for pharmaceutical lifecycle management

No salary listed

Memphis, TN, USA

In Person

Bachelor's

Category
Operations & Logistics (1)
Required Skills
Data Analysis

Get referred to EVERSANA

See people who can refer or advise you

Requirements
  • Bachelor’s degree or equivalent combination of education and experience
  • Minimum of 5 years of strong supervisory experience in an hourly administrative employee environment, preferably in an office role supporting a distribution center’s administration needs including planning and scheduling orders and deliveries. Pharma experience is preferred by not required
  • Proficient in managing administrative workflows and optimizing operational processes
  • Strong analytical skills with the ability to interpret data, identify trends, and make informed decisions
  • Demonstrated problem-solving capabilities, including the ability to assess complex situations and implement effective solutions
  • Collaborative leadership style with a focus on cross-functional alignment and shared success
  • Exceptional verbal and written communication skills, with the ability to influence and engage stakeholders at all levels
  • Strong customer-centric mindset with a commitment to service excellence
  • Highly organized with the ability to manage multiple priorities and deadlines effectively
  • Dependable and accountable, with a track record of delivering results
Responsibilities
  • Lead, coach, and develop a high-performing Data Management team, providing regular feedback, performance evaluations, and career development opportunities
  • Foster a culture of accountability, continuous learning, and collaboration
  • Ensure new team members are effectively onboarded and trained across all relevant systems and processes
  • Oversee daily operations of and client communications to ensure accuracy, timeliness, and compliance with service level agreements
  • Monitor team workload and proactively adjust task assignments to meet volume demands and service expectations
  • Serve as the point of escalation for complex client or customer issues and ensure timely resolution
  • Partner with leadership to identify, recommend, and implement process improvements that enhance productivity, quality, and client satisfaction
  • Utilize metrics and KPIs to monitor team performance, drive operational improvements, and report progress to senior leadership
  • Lead initiatives to document, standardize, and optimize workflows, including SOPs and work instructions
  • Act as a liaison between various cross-functional teams including Distribution Operations, Supply Chain, Order to Cash, Finance, IT, Serialization, and Client Success to support seamless daily execution/escalations
  • Participate in strategic planning and special projects to support departmental and organizational goals
  • Ensure a positive client experience through consistent service delivery, proactive communication, and timely issue resolution
  • Represent in client calls or meetings as needed to address operational updates or performance discussions
  • Maintain adherence to internal controls, data accuracy standards, and regulatory compliance related to order processing and client communications
  • Monitor system and process integrity, ensuring pricing, credits, and order entry are executed without errors or delays
  • Model inclusive behaviors and create an equitable environment where all team members feel valued and empowered
  • Demonstrate a commitment to diversity, equity, and inclusion through continuous development, modeling inclusive behaviors, and proactively managing bias
  • Support hands-on execution of operational tasks during peak periods or resource gaps
  • All other duties as assigned
  • Execute the goals established by the business and department to ensure client delight
  • Effectively delegate tasks, responsibility, and accountability to teams to ensure execution is performed to a standard of excellence
  • Lead their team and improve the quality of the departments work product
  • Assess and determine appropriate personnel and structure to accomplish necessary day-to-day functions
  • Interview, select, and supervise the activities of the department staff within the confines of stated business goals and company policies & procedures

EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Milwaukee, Wisconsin

Founded

2018

Get referred to EVERSANA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EVERSANA signed Candel Therapeutics and Xcovery launch deals in 2026, expanding pipeline.
  • Mike Guarino and Jen Norton appointments strengthen agency and market-access leadership in 2026.
  • August 20, 2026 platform expansion supports cross-sell into medical, commercial, and access teams.

What critics are saying

  • Integration risk remains high after the August 2025 Waltz merger and APACME carve-out.
  • Large clients can insource AI commercialization, shrinking EVERSANA's agency and services revenue in 2027.
  • If Candel's CAN-2409 launch or similar launches fail, EVERSANA loses marquee growth proof.

What makes EVERSANA unique

  • August 2026 AI Agency spans medical affairs, market research, field sales, and MLR automation.
  • EVERSANA combines commercialization, distribution, patient services, and payer connectivity inside one operating model.
  • The 2025 Waltz Health merger adds drug-pricing marketplaces and direct-to-payer capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 20th, 2026
EVERSANA expands AI-powered platform across medical affairs and commercial operations

EVERSANA has expanded its AI-powered commercialisation platform beyond marketing to include medical affairs, market research, and field sales team engagement. The platform, which combines agentic AI orchestration, workflow automation, and enterprise data capabilities, now offers solutions for medical information, market research, MLR automation, and analytics. The company is developing additional features for market access, patient services, and sales enablement. The platform aims to help life sciences organisations improve efficiency whilst maintaining industry compliance and governance requirements. "Organizations are moving beyond isolated AI pilots and looking for practical ways to scale AI across commercialisation," said Mark Thierer, EVERSANA's chief executive officer. The company serves more than 650 organisations globally. EVERSANA will showcase the platform at an event on 27 August in New York.

PR Newswire
Jun 9th, 2026
EVERSANA appoints Jen Norton as President of Market Access & Value to lead integrated business unit

EVERSANA, a global provider of commercial services to the life sciences industry, has appointed Jen Norton as President, Market Access & Value. Norton will lead a new dedicated market access business unit integrating EVERSANA's services across global pricing, revenue management, value and evidence, and consulting. Norton brings over 20 years of market access leadership experience. She joins from Takeda, where she served as Senior Vice President and Head of U.S. Patient and Market Access, and previously held senior positions at Amgen and Biogen. The new unit reinforces EVERSANA's commitment to helping clients navigate the complex pricing and access landscape. CEO Mark Thierer said successfully navigating market access is amongst the most critical challenges clients face today. EVERSANA serves over 650 organisations in the life sciences industry.

PR Newswire
May 6th, 2026
EVERSANA appoints Mike Guarino as CEO of global health agency EVERSANA INTOUCH

EVERSANA has appointed Mike Guarino as chief executive officer of EVERSANA INTOUCH, its global health agency. Guarino will lead strategy and operations across the agency's capabilities, focusing on integrating commercialisation opportunities through data and AI to deliver marketing solutions for life sciences clients. Guarino brings extensive agency experience, most recently serving as chief commercial officer at IPG Health. He spent over two decades in senior roles at FCB Health and co-founded Area 23. Senior leaders including Ann Cave, Susan Perlbachs, John Kenny and Dan Gandor will report to Guarino. Founder Faruk Capan will shift focus to expanding the company's AI Agency platform, launched in collaboration with Google in August 2025. EVERSANA provides commercial services to the life sciences industry, serving over 650 organisations globally.

PharmaLIVE
Apr 29th, 2026
Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy.

Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy. Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement with EVERSANA, a provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer. Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access, and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel's virtual Research and Development Day in December 2025. This collaboration reflects Candel's deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer, subject to regulatory approval. This operating model gives Candel access to leading commercial capabilities while maintaining financial flexibility, capital efficiency, and scientific focus that has driven Candel's progress to date. "From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "With the addition of EVERSANA, that model is fully in place, and with the progress we've already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer. We look forward to working with EVERSANA and IDEA Pharma in providing a novel and potentially invaluable therapeutic for localized prostate cancer patients." "We are proud to support Candel as it advances what could be a new and potentially transformative treatment option for patients with localized prostate cancer," said Gregory Skalicky, President of EVERSANA. "Candel's unique approach to commercialization, building a dedicated and flexible platform with specialized partners, rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support. We have already integrated our resources alongside the Candel team, with key commercial workstreams actively underway, and we look forward to helping ensure that aglatimagene reaches patients efficiently and effectively upon potential approval."

PR Newswire
Apr 27th, 2026
Xcovery partners with EVERSANA to expand US launch of lung cancer drug Ensacove

Xcovery Holdings has partnered with EVERSANA to support the US commercial launch of Ensacove (ensartinib), a novel therapy for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. Under the agreement, EVERSANA will provide comprehensive end-to-end commercialisation services, including market access and commercial and medical teams. Ensacove is a next-generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals and is now available in the United States. The partnership aims to expand patient access across the US by leveraging EVERSANA's commercialisation capabilities and experience in the life sciences industry. EVERSANA serves over 650 organisations globally, including pharmaceutical startups and established companies.

INACTIVE